Keros Therapeutics, Inc. Common Stock (KROS) is a publicly traded Healthcare sector company. As of November 5, 2026, KROS trades at $9.45 with a market cap of $214.73M and a P/E ratio of 5.17. KROS moved -13.25% today. Year to date, KROS is -47.57%; over the trailing twelve months it is -39.97%. Its 52-week range spans $9.12 to $22.55. Analyst consensus is buy with an average price target of $18.80. Rallies surfaces KROS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
KROS financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. KROS recently traded at $9.45. Market cap is $214.73M. P/E ratio is 5.17. Revenue is $243.86M.
| Metric | Value |
|---|---|
| Price | $9.45 |
| Market Cap | $214.73M |
| P/E Ratio |
| 5.17 |
| EPS | $2.34 |
|---|
| Dividend Yield | 0.00% |
|---|
| 52-Week High | $22.55 |
|---|
| 52-Week Low | $9.12 |
|---|
| Volume | 216.88K |
|---|
| Avg Volume | 0 |
|---|
| Revenue (TTM) | $243.86M |
|---|
| Net Income | $87.01M |
|---|
| Gross Margin | 0.00% |
|---|
6 analysts cover KROS: 0 strong buy, 3 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $18.80.